Advertisement

Topics

Achillion Company Profile

01:24 EST 18th November 2017 | BioPortfolio

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion’s drug development pipeline is led by elvucitabine (Beta-L-Fd4C or ACH-126,443), which is currently in late-stage Phase 2 clinical trials for the treatment of patients infected with HIV. Achillion’s candidate for the potential treatment of HCV infection, ACH-806, is in a Phase 1 clinical trial and is anticipated to be completed by the first half of 2006.

Location

300 George Street
New Haven,
Connecticut
06511
United States of America

Contact

Phone: 203-624-7000
Fax: 203-624-7003
Email: info@achillion.com


News Articles [64 Associated News Articles listed on BioPortfolio]

J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion's stock

Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to develop the firm’s hepatitis C drug pipeline. The news sent Achillion’s stock re...

USPTO Grants Composition of Matter Patent to Achillion for ACH-4471,...

Achillion Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued a U.S. Patent to Achillion for ACH-4471. U.S. Patent No.

-$0.18 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter

Wall Street brokerages expect Achillion Pharmaceuticals, Inc. to announce earnings per share of for the current quarter, Zacks reports. Zero analysts have provided estimates for Achillion Pharmaceutic...

-$0.15 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter

Equities analysts expect that Achillion Pharmaceuticals, Inc. will post earnings of per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Achillio...

ACHTUNG Kurseinbruch bei Achillion Pharmaceuticals-Aktie! - Aktiennews

Bad Marienberg - +++ ACHTUNG +++ Kurseinbruch bei Achillion Pharmaceuticals-Aktie! - Aktiennews Achillion Pharmaceuticals-Aktienanalyse des Analysten Brian Skorney von Robert W. Baird: Der Aktienku...

Zacks: Brokerages Expect Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.18 EPS

Brokerages forecast that Achillion Pharmaceuticals, Inc. will post earnings per share for the current quarter, according to Zacks . Zero analysts have made estimates for Achillion Pharmaceuticals'...

Achillion Pharmaceuticals (ACHN) - Termination of coverage

Edison Investment Research - Pharmaceutical & healthcare - Achillion Pharmaceuticals: Edison Investment Research is terminating coverage on Achillion Pharmaceuticals (ACHN). Please note you should no ...

Analysts Expect Achillion Pharmaceuticals, Inc. (ACHN) Will Announce Earnings of -$0.16 Per Share

Brokerages expect that Achillion Pharmaceuticals, Inc. will post earnings of per share for the current quarter, according to Zacks Investment Research . Zero analysts have provided estimates for Achil...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.

The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Stud...

Study of Once Daily Elvucitabine Versus Lamivudine in Subjects With a Documented M184V Mutation

HIV-1 infected patients receiving long-term therapy with lamivudine or emtricitabine (nucleoside reverse transcriptase inhibitors [NRTIs]) are at risk for the development of a mutation at ...

Companies [2 Associated Companies listed on BioPortfolio]

Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s discovery and development teams have advanced mult...

Achillion Pharmaceuticals

Achillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, ...

More Information about "Achillion" on BioPortfolio

We have published hundreds of Achillion news stories on BioPortfolio along with dozens of Achillion Clinical Trials and PubMed Articles about Achillion for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Achillion Companies in our database. You can also find out about relevant Achillion Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record